Next Article in Journal
Can Novel Treatment of Age-Related Macular Degeneration Be Developed by Better Understanding of Sorsby’s Fundus Dystrophy
Next Article in Special Issue
Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications
Previous Article in Journal
Neuroendocrine Disturbances after Brain Damage: An Important and Often Undiagnosed Disorder
Previous Article in Special Issue
Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(5), 858-873; doi:10.3390/jcm4050858

Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics

Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY 10029, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Sebastien Barbarot and Kim Thomas
Received: 16 March 2015 / Revised: 20 April 2015 / Accepted: 21 April 2015 / Published: 29 April 2015
(This article belongs to the Special Issue Epidemiology and Treatment of Atopic Eczema)
View Full-Text   |   Download PDF [134 KB, uploaded 29 April 2015]

Abstract

Atopic dermatitis (AD) is the most common inflammatory skin disease. Recent research findings have provided an insight into the complex pathogenic mechanisms involved in this disease. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are still lacking. Biomarkers of lesional, nonlesional skin, and blood have been developed for baseline as well as after treatment with broad and specific treatments (i.e., cyclosporine A and dupilumab). These biomarkers will help with the development of novel targeted therapeutics and assessment of disease reversal, with the promise of a more personalized treatment approach. Since AD involves more than one subtype (i.e., intrinsic/extrinsic, pediatric/adult, etc.), these molecular fingerprints needs to be validated in all subpopulations with AD. View Full-Text
Keywords: atopic dermatitis; eczema; biomarker; translational revolution; T-cells; intrinsic; extrinsic; immune phenotype atopic dermatitis; eczema; biomarker; translational revolution; T-cells; intrinsic; extrinsic; immune phenotype
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mansouri, Y.; Guttman-Yassky, E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J. Clin. Med. 2015, 4, 858-873.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top